Acquisition of multi-mode, high-resolution, high-sensitivity imaging platform

项目总结/摘要 该申请要求资金购买台风5成像平台，迫切需要更换， 升级共享仪器池（SIP）核心中过时且不再受工厂支持的Typhoon 9500 科罗拉多大学博尔德分校生物化学系的设施。台风5号是一种高灵敏度， 高分辨率成像平台，用于蛋白质，RNA， DNA、小分子和复合物。多模式成像仪包括放射性同位素的磷光成像 标记样品，多色荧光检测（红色、绿色、蓝色和两个近红外通道）， 量热密度法和有限的化学发光法。它可以成像在许多不同的目标，包括 磷酸存储屏、凝胶、膜、TLC板、多孔板和微阵列。的广泛 生物分子成像能力对于CU Boulder的许多生物医学研究项目至关重要。 SIP提供尖端仪器和维护良好的基础研究的组合 为CU研究社区提供仪器仪表。核心设施广泛和积极影响许多生物医学 研究计划，但这需要获得和维护先进的，最先进的 仪器仪表在过去五年，现时在SIP的台风9500已为182名个人用户提供服务， 31个研究小组在5个部门和研究所在CU博尔德。一个由12个研究实验室组成的核心小组，包括 10个NIH资助的小组（共15个正在进行的NIH资助的项目）和来自三个国家的两名早期研究人员 部门-目前在很大程度上依赖于台风的成像能力。该成像仪用于 收集可验证的数据（例如，活性测定、结合化学计量、测序凝胶等）， 质量控制和优化下游实验的样品。新的台风5号将服务于现有的 生物医学研究项目，并将增加新的能力，在近红外两个额外的荧光通道 用于提高灵敏度和改善具有挑战性的样品的信噪比。 SIP中的新台风5将提供给CU Boulder的所有研究小组，并得到良好的支持- 建立了管理和财务结构，为SIP及其研究界提供了良好的服务， 10年SIP工作人员将提供专业知识和帮助，从实验设计到培训，数据收集，故障排除， 和数据分析。这一强有力的支持结构使新的和现有的用户能够进行试点研究， 测试新的实验和研究项目。它增加了成功率，并最大限度地减少了经济负担 对于研究小组来说。这对于生物医学研究的未来至关重要，并将对许多新的研究产生积极影响 研究计划在CU博尔德从创新，基础研究寻求了解的基本 控制人类生命和健康的机制（例如基因调节，细胞信号传导，膜生物学，衰老， 以及更多）转化研究，例如，开发新的药物靶点，新的治疗性小分子， 抗微生物剂和药物递送方法。

Project Summary/Abstract This application requests funds to acquire a Typhoon 5 imaging platform, urgently needed to replace and upgrade the outdated and no longer factory-supported Typhoon 9500 in the Shared Instruments Pool (SIP) core facility in the Department of Biochemistry, University of Colorado Boulder. The Typhoon 5 is a high-sensitivity, high-resolution imaging platform for the imaging, characterization, and precise quantification of proteins, RNA, DNA, small molecules, and complexes. The multimode imager includes phospho imaging for radioisotope labeled samples, multi-color fluorescence detection (red, green, blue, and two near-infrared channels), calorimetric densitometry, and limited chemiluminescence. It can image in many different targets, including phospho storage screens, gels, membranes, TLC plates, multiwell plates, and microarrays. The extensive biomolecular imaging capabilities are essential for many biomedical research programs at CU Boulder. SIP provides a combination of cutting-edge instrumentation and well-maintained basic research instrumentation to the CU research community. The core facility widely and positively impacts many biomedical research programs at CU-Boulder, but this requires acquiring and maintaining advanced, state-of-the-art instrumentation. The current Typhoon 9500 in SIP has over the last five years served 182 individual users from 31 research groups in 5 departments and institutes at CU Boulder. A core group of 12 research labs - including 10 NIH-funded groups (a total of 15 ongoing NIH-funded projects) and two early-stage investigators from three departments - is currently relying heavily on the imaging capabilities of the Typhoon. The imager is used to collect publishable data (e.g., activity assays, binding stoichiometry, sequencing gels, and much more) and to quality control and optimize samples for downstream experiments. The new Typhoon 5 will serve existing biomedical research projects and will add new capabilities with two additional fluorescence channels in the NIR for increased sensitivity and improved signal-to-noise for challenging samples. The new Typhoon 5 in SIP will be available to all research groups at CU Boulder supported by the well- established management and financial structure that has served SIP and its research community well for the last 10 years. SIP staff will offer expertise and aid from experiment design to training, data collection, troubleshooting, and data analysis. This strong support structure empowers new and existing users to conduct pilot studies to test new experiments and research projects. It increases the success rate and minimizes the financial burden for research groups. This is essential for the future of biomedical research and will positively impact many new research programs at CU Boulder from innovative, basic research seeking to understand the fundamental mechanisms that govern human life and health (e.g. gene regulation, cell signaling, membrane biology, aging, and more) to translational research, for example, developing new drug targets, new therapeutic small molecules, antimicrobials, and drug delivery methods.